Following embolization, we initiate treatment with sirolimus, a well-established mTOR inhibitor, which has proven effective in the treatment of vascular malformations with a high proliferation rate and has similarly been used in treatment of KHE [48–50]. This evidence concerns the gene MTOR and kaposiform hemangioendothelioma.